Mercalis

What Mercalis does

Mercalis (formerly TrialCard) is a privately held U.S. life sciences commercialization services company headquartered in Morrisville, NC, with a 501–1,000 employee base and a history dating to 2000. Operating under the Valeris brand, the company delivers an integrated end-to-end partnership to pharmaceutical and life sciences clients across three solution pillars: Insights and Data (strategy consulting, market access intelligence), Patient Support Services (patient access and affordability, non-commercial dispensing pharmacy, nursing support, patient engagement and adherence, eServices Curator, virtual clinical trial supply), and Healthcare Provider Engagement (contract sales teams, field reimbursement support, medical science liaisons, clinical nurse educators, institutional sales support). Reported scale includes 500+ life sciences partners, 44M+ patients supported, and $34B+ in patient savings facilitated.

The technology stack centers on proprietary platforms including Valeris Vantage (real-time guidance and data insights for patient support teams), Valeris eServices Curator (digital patient engagement tooling), and RxStudy Card (clinical trial supply and virtual clinical trial logistics). These platforms sit on top of an operational infrastructure built through five disclosed acquisitions between 2019 and 2022 (RxSolutions, Mango Health, Policy Reporter, Archer Healthcare, and Triangle Insights Group), which extended Mercalis into adherence technology, policy intelligence, healthcare services, and strategy consulting. The rebrand from TrialCard to Mercalis/Valeris repositioned the company from a co-pay card vendor into a full-spectrum commercialization platform.

Mercalis makes money through managed-services and enterprise engagements with life sciences companies, operating a direct enterprise field sales motion. Pricing is not publicly disclosed and is quote-based per client engagement. The company targets a single vertical segment — life sciences companies — and has been capitalized by a 2011 Goldman Sachs funding round alongside ongoing acquisition-led growth. Geographic distribution is described as global, though specific international footprint is not detailed in available sources.

Name

Mercalis

Legal name

Mercalis

Website

https://mercalis.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Mercalis (Valeris) is a U.S. life sciences commercialization services company serving pharmaceutical clients with integrated patient support, market access insights, and healthcare provider engagement delivered through proprietary platforms and a 501–1,000 person enterprise field operation.

Ownership category

akta.pro rank

Product category

Life Sciences Commercialization Services

NAICS

Scientific Research and Development Services (5417), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Services-Health Services (8000), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Clinical Trial Logistics & Depot Services (IRT-integrated, kitting, returns) (HLAGAMAC)

akta.pro secondary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Life sciences commercialization
• Patient support services
• Market access intelligence
• Healthcare provider engagement
• Pharma commercial solutions

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Commercial Solutions Services: Integrated life sciences and pharmaceutical commercialization services spanning insights and data, patient support services, and healthcare provider engagement. Services are delivered as an end-to-end partnership model for life sciences companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Mercalis (operating commercially under the Valeris brand) delivers integrated life sciences and pharmaceutical commercialization services to pharmaceutical and biotech companies. Its offering combines insights and data, patient support services (including access, affordability, non-commercial dispensing pharmacy, nursing support, engagement/adherence, and virtual clinical trial supply), and healthcare provider engagement (contract sales, field reimbursement, medical science liaisons, clinical nurse educators) as an end-to-end partnership from value discovery to delivery.

Product overview

Mercalis is a life sciences and pharmaceutical commercialization services company that delivers integrated solutions across patient support, healthcare provider engagement, and data-driven insights. The company's offering consists of a unified platform with specialized modules including patient access and affordability programs, non-commercial dispensing pharmacy services, nursing support services, patient engagement and adherence tools, and healthcare provider outreach solutions including contract sales teams, field reimbursement support, medical science liaisons, and clinical nurse educators. The portfolio is anchored by branded products such as RxStudy Card for clinical trial supply and Valeris Vantage for real-time data analytics. Mercalis has grown through acquisitions including Triangle Insights Group (2022) and Archer Healthcare (2021), expanding its capabilities in insights consulting and market access intelligence.

Differentiator

Problem solved

Functional benefit

Brands

• Valeris: Life Sciences & Pharma Commercial Solutions - integrated services for pharmaceutical commercialization including insights, patient support, and healthcare provider engagement.
• Valeris eServices Curator
• Valeris Vantage
• RxStudy Card

Products and services

• RxStudy Card

Quantifiable outcome

• $34B+ in patient savings through affordability and support programs
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Triangle Insights GroupcoreStrategic or Co-development Partner · 12 April 2022Acquired by Mercalis (formerly TrialCard) on April 12, 2022. Triangle Insights Group provides strategy consulting services within the life sciences commercialization space, complementing Mercalis' existing patient support and access capabilities.
• Archer HealthcarecoreStrategic or Co-development Partner · 4 November 2021Acquired by Mercalis (formerly TrialCard) on November 4, 2021. Archer Healthcare contributed healthcare-focused capabilities to expand Mercalis' integrated commercial solution offerings in the life sciences sector.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Global life sciences services giant spanning R&D, real-world evidence, and commercial/contract sales. Comparable as an end-to-end pharma commercialization provider, but materially larger and more diversified than Mercalis.
• Syneos Health: Clinical and commercial solutions provider for biopharma, with contract sales, patient access, and medical affairs capabilities directly overlapping Mercalis' Valeris offering.
• Inizio (Ashfield + UDG): Multi-brand commercialization and communications platform including Ashfield's contract sales, MSL, and patient solutions — overlapping with Mercalis' HCP engagement and patient support lines.
• Publicis Health: Large healthcare communications and HCP engagement network within Publicis Groupe. Comparable in HCP-facing commercialization services but operates at much greater scale across multiple agencies.

Direct peers

• Eversana: Integrated life sciences commercialization services firm with patient services, HCP engagement, market access, and data analytics — the closest head-to-head comparable to Mercalis/Valeris.
• Precision Medicine Group: Specialty commercialization services including patient access, medical affairs, and market access for emerging biopharma — comparable in customer base and integrated service model.
• Real Chemistry: Integrated marketing, communications, and data-driven commercialization services for life sciences brands, comparable in HCP engagement and analytics-led patient solutions.
• The Lockwood Group: Medical communications, MSL, and patient solutions provider with pharma commercialization focus, comparable in service mix to Mercalis' medical affairs/patient engagement lines.
• EVERSANA (revenue management arm): Listed once as primary but Eversana's patient services and dispensing pharmacy offerings overlap directly with Mercalis' non-commercial dispensing pharmacy and patient access programs.

Emerging players

• PharmaLex: Consulting and services firm spanning regulatory, market access, and patient services — comparable to the Triangle Insights Group consulting arm acquired by Mercalis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/_mercalis
• Facebookfacebook.com/trialcard
• LinkedInlinkedin.com/company/mercalisinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mercalis